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Double cyclization of short linear peptides obtained by solid phase peptide synthesis was used to prepare
bridged bicyclic peptides (BBPs) corresponding to the topology of bridged bicyclic alkanes such as
norbornane. Diastereomeric norbornapeptides were investigated by 1H-NMR, X-ray crystallography and
CD spectroscopy and found to represent rigid globular scaﬀolds stabilized by intramolecular backbone
hydrogen bonds with scaﬀold geometries determined by the chirality of amino acid residues and sharing
structural features of b-turns and a-helices. Proteome proﬁling by capture compound mass
spectrometry (CCMS) led to the discovery of the norbornapeptide 27c binding selectively to calmodulin
as an example of a BBP protein binder. This and other BBPs showed high stability towards proteolytic
degradation in serum.Introduction
The recurring problem of high attrition rates in drug develop-
ment has led to questioning whether the types of molecules
investigated as drugs should be reconsidered from rst princi-
ples.1 Among various approaches to address this problem, there
has been a renewed interest in peptide-based drugs.2 Peptides
are easily prepared by solid-phase peptide synthesis (SPPS),3
cover an intermediate size range otherwise diﬃcult to access,
and are suitable for targets with large binding sites such as
protein–protein interaction interfaces.4 Linear peptides
however have poor drug properties since they are rapidly
degraded in serum,5 and show limited membrane penetration
ability6 and oen weak and unselective target binding due to
conformational exibility.7 These limitations can be overcome
by rigidifying the structure by cyclization,8 which decreases the
entropy penalty of binding, increases target selectivity, and may
reduce or entirely suppress serum proteolysis.9 Cyclization may
involve peptide bond formation to form a so-called homodetic
cyclic peptide or macrolactonization to form depsipeptides,10 as
well as disulde or thioether bridge formation as in cyclotides11, University of Berne, Freiestrasse 3, 3012
nd@dcb.unibe.ch; Fax: +41 31 631 80 57
de Lausanne, 1015 Lausanne, Switzerland
ny
(ESI) available: Crystallographic data;
HPLC proles and MS spectra. CCDC
and crystallographic data in CIF or
c5sc01699a
hemistry 2015and lantibiotics,12 and other types of connections between
amino acid side-chains.13 Further modications contributing to
improved properties include the use of non-natural and D-
amino acids14 and peptide bond N-methylation,15 all of which
are found in various peptide natural products mostly of bacte-
rial origin.
Recently we proposed a strategy to expand the chemical
space of bioactive peptides based on mathematical graphs.16 In
analogy to small molecule graphs where graph nodes corre-
spond to atoms and graph edges to covalent bonds,17 peptide
graphs result from assigning graph nodes to amino acids and
graph edges to peptide bonds. While only linear and cyclic
peptides are obtained when using only monovalent (terminal)
and divalent (intra-chain) nodes, introducing branching points
in the peptide chains in form of diamino acids (e.g. lysine) or
amino diacids (e.g. glutamic acid) leads to a diversity of possible
polycyclic peptide topologies as potential new types of con-
strained peptides, in particular bridged bicyclic peptides
(BBPs). BBPs represent a vast molecular class comprising up to
3.1 x 1019 possible members derived from 97 bicyclic graphs
with up to 15 residues taken from 20 proteinogenic amino
acids. Expanding from only a handful of examples in the liter-
ature prepared by solution phase synthesis,18 we recently
showed that BBPs can be obtained by solid-phase peptide
synthesis (SPPS) and on-resin cyclization to a monocyclic
peptide, followed by a second cyclization in solution coupling
the C-terminal carboxyl group with the 3-amino group of a lysine
side-chain to form the nal product, a strategy which is also
followed for the present paper (Scheme 1).19 The bridgehead
chirality was chosen such as to present the amino- and carboxyl-Chem. Sci., 2015, 6, 5473–5490 | 5473
Table 1 Synthesis of norbornapeptides (Scheme 1)
No. Sequencea mg Yieldb (%) [M + H]+ calc./obs.c
1 l1Gk2fPE1a2 34.9 82 725.40/725.40
2 l1Gk2fPE1A2 25.9 60 725.40/725.40
3 l1Gk2FPE1a2 11.4 56 725.40/725.40
4 L1Gk2fPE1a2 35.2 56 725.40/725.40
5 l1Gk2FPE1A2 8.6 59 725.40/725.40
6 L1Gk2fPE1A2 22.4 61 725.40/725.40
7 L1Gk2FPE1a2 17.5 36 725.40/725.40
8 L1Gk2FPE1A2 34.3 81 725.40/725.40
9 L1GK2FPE1A2 6.6 27 725.40/725.40
10 l1Gk2yPE1a2 8.9 4* 741.39/741.39
11 l1Gk2yPE1A2 10.9 59 741.39/741.42
12 l1Gk2YPE1a2 4.7 37 741.39/741.42
13 L1Gk2yPE1a2 21.8 73 741.39/741.40
14 l1Gk2YPE1A2 7.0 49 741.39/741.43
15 L1Gk2yPE1A2 20.5 42 741.39/741.39
16 L1Gk2YPE1a2 18.1 72 741.39/741.41
17 L1Gk2YPE1A2 7.3 15 741.39/741.45
18 L1GK2YPE1A2 13.8 37 741.39/741.40
19 k1Gk2fPE1a2 7.6 3* 740.41/740.41
20 l1Sk2fPE1a2 23.4 10* 755.41/755.41
21 l1Gk2fKE1a2 7.7 3* 756.44/756.44
22 k1Gk2ePE1c2 7.4 3* 754.36/754.36
23 K1Gk2fPE1A2 15.0 15* 740.41/740.41
24 L1Sk2fPE1A2 12.2 6* 755.41/755.41
25 L1Gk2fKE1A2 12.0 5* 756.44/756.44
26 K1Gk2ePE1C2 5.3 3* 754.36/754.36
a One-letter code for amino acids, upper case¼ L-, lower case¼ D-amino
acids, sequences are given as prepared by SPPS written from N- to C-
terminus, superscript numbers indicate residues involved in amide
bond ring closures in 1st (1) and 2nd (2) cyclization. b Yields of HPLC
puried products are given for the second cyclization reaction;
asterisks mark total yields (SPPS and second cyclization). In all cases,
yields are calculated for the corresponding triuoroacetate salts. c ESI-
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View Article Onlinegroup on the same stereotopic face of the monocyclic peptide,
which favoured the second cyclization. The X-ray crystal struc-
ture of a bicyclo[3.3.2]decapeptide established that BBPs cyclize
to form a concave bicyclic system20 with the bridgehead amino
acid H–C(a) proton pointing outwards.21
Herein we investigate the properties of BBPs as drug scaf-
folds. In drug design scaﬀolds are core structural elements,
mostly polycyclic systems (e.g. benzofurans, steroids, benzodi-
azepines, etc.), that appear decorated with various substituents
in drug molecules.22 Ideally, the scaﬀold chemistry is chosen
such that substituents can be varied easily using a conserved
synthetic approach.23 In the area of peptides, typical scaﬀold
approaches include various a-helix mimetics such as poly-
phenyls on which residue side-chains can be graed,24 cyclic
peptides,25 and b-hairpin mimetics which can be incorporated
into existing peptide sequences.26
We focus on diastereomers and side-chain analogs of nor-
bornapeptide 1 which represents an expanded form of the
parent hydrocarbon scaﬀold norbornane (Scheme 1). Structural
studies by X-ray crystallography, 1H-NMR and CD spectroscopy
show that these BBPs mostly exist as single conformers adopt-
ing a rigid structure stabilized by several intramolecular back-
bone hydrogen bonds. The relative orientation of side chains is
determined by the chirality of the various residues as well as by
interactions between side-chains within the constrained BBP
geometry. A proteome proling experiment by capture
compound mass spectrometry (CCMS)27 using photoreactively
labeled norbornapeptides is reported leading to the discovery of
27c binding selectively to calmodulin as an example of a BBP
protein binder. In contrast to linear peptides this and other
BBPs are shown to be stable towards serum degradation.Scheme 1 Synthetic schemes for bridged bicyclic peptides without
protected side chains (1–20) or with Boc protected side chains (21–
26), exempliﬁed with norbornapeptides 1 and 10. One letter codes are
used for amino acids, upper case letters ¼ L-amino acids, lower case
letters ¼ D-amino acids, italics ¼ branching amino acids, arrow bonds
indicate peptide bonds in C/N direction. Conditions: (a) Fmoc SPPS;
(b) Pd(PPh3)4, PhSiH3, anh. CH2Cl2; (c) piperidine–DMF 1 : 4; (d) HATU,
iPr2EtN, NMP–DMSO 4 : 1; (e) Wang resin–PG ¼ Boc : CF3CO2H–
iPr3SiH–H2O 94 : 5 : 1, chlorotrityl resin–PG ¼ Mtt: 1% CF3CO2H in
CH2Cl2; (f) HATU, iPr2EtN, CH2Cl2–DMF 20 : 1; (g) only for chlorotrityl
resin–PG ¼ Mtt route: CF3CO2H–CH2Cl2 4 : 1.
MS spectra (positive mode) were recorded on a LTQ OrbitrapXL
hybrid ion trap-Orbitrap mass spectrometer.
5474 | Chem. Sci., 2015, 6, 5473–5490Results and discussion
Synthesis of diastereomeric norbornapeptides
Diastereoisomers and side-chain analogs of norbornapeptide 1
were prepared by Fmoc-SPPS using either the original protocolTable 2 Amide proton temperature coeﬃcients indicating intramo-
lecularly H-bonded protons in diastereomeric norbornapeptides 1–9a
1 2 3b 4 5 6 7b 8 9
L/D-Leu1-HN 7.3 8.1 3.7 7.7 7.8 8.5 6.8 7.8 7.2
Gly2-HN 7.9 7.7 4.4 6.8 7.0 7.9 6.2 7.6 7.9
L/D-Lys3-HN 8.8 3.1 2.4 2.1 1.3 2.8 1.4 2.0 1.6
L/D-Phe4-HN 6.6 7.2 5.2 5.3 10.0 8.0 6.3 8.8 9.2
L-Glu6-HN 1.7 2.3 1.0 1.2 1.2 1.2 1.8 1.5 7.2
L/D-Ala7-HN 3.0 7.6 0.3 1.4 9.6 6.2 9.9 9.0 8.3
L/D-Lys3-HN3 6.6 7.3 n.d. 4.3 6.6 6.6 n.d. 6.5 2.0
a Coeﬃcients in Dd/DT (ppb K1). Fully H-bonded protons (boldface)
have Dd/DT < 4.0 ppb K1 and partially H-bonded protons have
Dd/DT ¼ 4.0–7.0 ppb K1. n.d. ¼ not determined. Low values
indicating intramolecular H-bonds are highlighted in bold.
b Coeﬃcient values given for the major conformer of the prolyl bond,
trans for 3 and cis for 7. Residue number according to the position in
the parent linear precursor (Table 1).
This journal is © The Royal Society of Chemistry 2015
Fig. 1 Structures of norbornapeptides determined by X-ray crystallography (yellow) or NMR (green). Intramolecular hydrogen bonds are marked
as black dashed lines. BBP 12 crystallized solely in the s-trans conformation of the Tyr4-Pro5 peptide bond, while both conformations occur in
solution for 12 and 16.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5473–5490 | 5475
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View Article Onlineon Wang resin, or a modied approach using a 2-chlorotrityl
resin as solid support and a 4-methyltrityl (Mtt) protected lysine
as the branching diamino acid. In both cases the rst cycliza-
tion was carried out on the resin between the N-terminus and
the side-chain carboxyl group of a glutamate residue released
from its allyl ester by Palladium catalyzed deprotection. The
second method on 2-chlorotrityl resin enabled the subsequent
cleavage of the C-terminal carboxyl group from the resin and
lysine side chain deprotection under weakly acidic conditions,
and was suitable to carry out the second cyclisation in solution
with sequences containing side-chain protected residues
(Scheme 1). These procedures were used to prepare the diaste-
reoisomeric series 1–18 and side-chain analogs 19–26 (Table 1).Fig. 2 Ramachandran plot of peptide bond torsional angles observed
in norbornapeptide structures for (A) L-residues and (B) D-residues.
Preferred (red) and allowed (yellow) regions as observed in protein
structures are highlighted. The (f, j) torsional angles in the unallowed
bottom right portion in (A) are at the a-carbon of L-leucine in 6.Structural studies
BBPs 1–18 were subjected to crystallisation screening either
under protein crystallisation conditions (aqueous buﬀers with
additives) or under small molecule crystallisation conditions
(organic solvents). The protein crystallisation screen, which had
succeeded earlier in the case of a bicyclo[3.3.2]decapeptide,21b
did not yield crystals in the present study. On the other hand the
tyrosine-containing norbornapeptide 10 yielded diﬀracting
crystals in a water–triuoroethanol–DMSO (7 : 2 : 1) mixture,
and its stereoisomers 12, 13 and 15 provided suitable crystals
from methanol. Although solvent molecules and H-atoms were
not always entirely resolved the structures were of suﬃcient
quality to unambiguously describe the BBP structures. In all
four cases, crystallisation was favoured by the formation of an
intermolecular H-bond between the tyrosine side-chain
hydroxyl groups (Tables S1–S20†).
The structure of BBPs 1–18 was furthermore established by
NMR spectroscopy. Proton resonances in 1H NMR spectra were
assigned from standard 1D and 2D experiments. The BBPs gave
single sets of signals with the exception of 3, 7, 12 and 16 where
two conformers appeared as distinct sets of signals which coa-
lesced to a single set around 90 C. Proton–proton distance
constraints were extracted from 2D ROESY NMR spectra and
used in a restrained molecular dynamics simulated annealing
(rMDSA) using ﬀ12SB force eld from AMBER12 package28 for 1
ns starting from a 3D-model derived from the experimental X-
ray structure of the BBP or its closest diastereoisomer. With the
output structure from rMDSA, another 1 ns non-restrained
simulation was implemented in explicit solvent. The averaged
structure over the last 10 frames of the MD simulations was
used as the nal structure, which was checked for consistency
by the presence of intramolecular hydrogen bonds identied as
temperature independent amide protons in the NMR spectra of
the phenylalanine series (1–9) mostly engaging the bridgehead
lysine a-NH and bridgehead glutamate a-NH (Table 2). In the
case of 5, 8, 9, 14 and 18 the structure obtained aer minimi-
zation starting from the closest X-ray structure was not consis-
tent, however a satisfactory NMR structure was obtained
starting the minimization from a model built using Maestro
(version 8.5).29 For BBP 3 and 7 existing as two equilibrating
phenylalanyl-proline s-cis/s-trans conformers the NMR signal
could not be assigned well enough for a structure5476 | Chem. Sci., 2015, 6, 5473–5490determination, however their tyrosine analogs 12 and 16 gave
satisfactory structures for both conformers. For BBPs 9 and 18
with mismatched bridgehead chirality (both bridgehead resi-
dues as L-enantiomers) the NMR structures could be resolved
with both possible bridge orientations. BBP 9 is shown with a
“bridge-up” stereochemistry and BBP 18 with a “bridge-down”
orientation corresponding to the solution with best t to
distance constraints. In total 22 diﬀerent structures were
obtained, including two pairs of equilibrating conformers
(Fig. 1).
For 10, 12, 13 and 15 the structures determined by NMR were
almost superimposable with their X-ray structure, with slight
variations in the orientation of the peptide backbone probably
reecting a small degree of conformational exibility. In all 22
structures determined (4 X-ray and 18 NMR structures) the
peptide bonds occurred in the more stable s-trans conformation
except for the occurrence of an s-cis arrangement in the
secondary amide bonds phenylalanyl-proline of 5, 8, 9, s-cis
tyrosinyl-proline of 14, 17, 18, and an s-cis/s-trans equilibrium in
the tyrosinyl-proline bond of 12 and 16. Almost all backbone
torsional angles resided within allowed regions of the Ram-
achandran plot, providing further evidence that the bicyclic
structure of the norbornapeptide did not induce unusual
conformational constraints on the peptide chain despite its
relatively constrained nature (Fig. 2).
In all determined structures at least two intramolecular
backbone hydrogen bonds were observed, in particular
involving the (a)NH of the bridgehead lysine and glutamate
residues. These intramolecular hydrogen bonds contributed to
scaﬀold rigidity, which was also evidenced by the existence of
single conformers in solution with the exception of the proline
s-cis/s-trans equilibria observed with 3, 7, 12 and 16 as discussed
above. Further evidence for the conformational rigidity of nor-
bornapeptides was provided by circular dichroism (CD) spectra.
Each BBP gave a specic circular dichroism (CD) signature
independent of the medium (water, 25% aqueous tri-
uoroethanol as folding inducer, or aq. 6 M guanidinium
chloride as denaturant, Fig. 3A). Furthermore CD spectra of
BBPs 19–26 having various amino acid side-chains but aThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineconserved backbone and residue stereochemistry also gave
comparable CD traces, showing that the backbone conforma-
tion was largely independent of the amino acid side-chains in
the selected positions (Fig. 3B). The only exception concerned
21 and 25, where the proline residue was substituted by a lysine,
in line with the key structural role played by proline in peptideFig. 3 Circular dichroism and 1H-NMR of norbornapeptides. (A). CD sp
phosphate buﬀer pH ¼ 7.0 (black), in 25% triﬂuoroethanol in aq. 10 mM
(blue). BBP 3 and 7 existing as equilibrating conformers were not consider
10 mM aq. Phosphate pH 7.0. (C). 1H-NMRmetrics on amide proton signa
variations of 1 (left) and 6 (right) and their side-chain analogs 10, 19–22
This journal is © The Royal Society of Chemistry 2015chains. The eﬀect was conrmed by the similarities in the 1H
NMR amide proton signal characteristics of these side-chain
analogs (Fig. 3C).
Despite of their rigidity the individual diastereomeric nor-
bornapeptides displayed diverse scaﬀold geometries reecting
the inuence of residue chirality on the overall structure. Whileectra of 1 and diastereomers 2, 4–6, 8, 9 (250 mg mL1) in aq. 10 mM
phosphate buﬀer pH ¼ 7.0 (red), and in aq. 6 M guanidinium chloride
ed. (B). CD spectra of 1, 6 and their side-chain analogs (350 mgmL1) in
ls of norbornapeptides. (C). Chemical shift and 3J values for side-chain
(to be compared to 1) and 15, 23–26 (to be compared to 6).
Chem. Sci., 2015, 6, 5473–5490 | 5477
Fig. 4 Eﬀect of single residue stereochemical inversion on BBP
structure. Pairwise alignment of a-carbons. Blue: 10; orange: 11;
yellow: 12; cyan: 13; grey: 14; magenta: 15.
Chemical Science Edge Article
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View Article Onlinefor pairs 10/12 and 13/15 a single stereochemical inversion of
phenylalanine respectively alanine only reoriented the side-
chain without aﬀecting the scaﬀold geometry as would occur in
the parent norbornane scaﬀold, inversion of the bridging
alanine in the pairs 10/11 and 12/14 induced a rearrangement of
the peptide backbone such that the diastereomeric pairs had
overall quite diﬀerent geometries (Fig. 4). These backbone
rearrangements were partly triggered by steric clashes between
the bridge alanine and the tyrosine respectively leucine side
chain, an eﬀect resulting from the bridged nature of the BBP
creating a 3D shape bringing side-chains close to one another, a
situation reminiscent of folded proteins, but which is not
observed in small monocyclic peptides which mostly adopt a
planar shape.30Secondary structures of BBP
The possible structural similarities between BBP scaﬀolds and
secondary structure elements of peptides and proteins was
analysed next. The dipeptide loops within the norbornapeptide
displayed the geometry of various types of b-turns, with three
cases of type I b-turn, fourteen cases of type II b-turns and six
cases of type VI b-turn. In the case of BBP 10, the tyrosine-
containing loop adopted a geometry not documented in known
b-turns, thus representing a new type of structural arrangement
(Fig. 5A).
While the seven residues of a norbornapeptide are very
diﬀerent from the seven residues of a-helix double turn in terms
of their topological connectivity, both backbones might present
several of their amino acid side chains in comparable orienta-
tion. To test this hypothesis, all residue triplets in each of the
norbornapeptide stereoisomers were compared pairwise with5478 | Chem. Sci., 2015, 6, 5473–5490all possible residue triplets in a seven-residue a-helix double
turn considering the relative positioning of the a-carbons, b-
carbon atoms, or both simultaneously. The comparisons were
carried out using an algorithm to optimize the spatial overlap
between atoms measured by an atom-pair tting function for
small molecule comparisons.31 Thirty-ve possible residue
triplets in the a-helix were compared with the nine norborna-
peptide diastereoisomers (Fig. S1†). The most similar triplet
sets were observed between alanine, tyrosine, leucine in BBP 16
and the 1st, 2nd and 7th residues from the double turn of a a-
helix, and between the corresponding residues in BBP 1 and 1st,
3rd and 7th residues from the double turn of a a-helix, sug-
gesting that norbornapeptides might serve as stable analogs of
a-helices for displaying three residues in these relative positions
(Fig. 5B and C).Identication of a protein binding BBP
To test whether BBP might show specic binding to proteins, a
proteomics based screening using capture compound mass
spectroscopy (CCMS)27 was carried out as a proof-of-principle
experiment. In CCMS proteins of a cell lysate binding speci-
cally to a small molecule drug are identied as those proteins
whose binding to a photoreactive, biotinylated analog of the
drug is diminished or suppressed in the presence of the unla-
beled drug as competitor. Proteins binding to the biotinylated
drug are identied by removing them with streptavidin coated
magnetic beads, washing, on-bead trypsin digestion and anal-
ysis of the resulting peptide fragments by LC/MSn.
To obtain functionalized BBPs suitable for the CCMS
experiment a modied synthesis was performed based on the
chloroacetyl cysteine thioether (ClAc) ligation for the second
cyclisation producing a BBP bearing a g-thia-homoglutamate as
the branching diamino acid (Scheme 2).32 In this ClAc approach
to BBPs a linear peptide was synthesized by Fmoc-SPPS on a
standard Rink-amide resin using an Alloc-protected lysine and a
side-chain allyl protected glutamate to close the rst cycle, and a
cysteine to form the second cycle at the end of the synthesis.
The rst cyclisation was performed on-resin between the
glutamate side-chain carboxyl group and the lysine side-chain
amino group aer Alloc/allyl deprotection. The N-terminal
Fmoc group was then removed, the free N-terminus chlor-
oacetylated, and the monocyclic peptide cleaved from the resin
and deprotected by acidic treatment and puried by preparative
HPLC. The second cyclisation was nally performed by ClAc
ligation between the cysteine thiol and the N-terminal chlor-
oacetyl group under basic conditions. This modied method
gave BBPs of comparable structure to the double amide bond
cyclization approach, but proved much more compatible with
multiple protected side-chains as required for the CCMS
experiment.
As possible protein binding BBPs three norbornapeptides
27c–29c were prepared displaying a pair of aromatic residues
(either phenylalanine or tryptophane) and two charged resi-
dues (glutamate, lysine or arginine) as side chains, hypothe-
sizing that a combination of charged and aromatic residues
might be favourable for protein binding. BBPs 27c–29cThis journal is © The Royal Society of Chemistry 2015
Fig. 5 Similarity of BBP to secondary structures. (A). b-Turns in the leucine-loop and tyrosine-loop. The b-turn present in the tyrosine-loop of 10
is further stabilized by a hydrogen bond connection with the alanine-bridge, generating an unusual b-turn geometry. (B). Double turn a-helix
with 1st, 2nd and 7th side chain highlighted and the corresponding BBP 16 shown in side-view (left) and top view (right). (C). Double turn a-helix
with 1st, 3rd and 7th side chain highlighted and the corresponding BBP 1 shown in side-view (left) and top view (right).
Scheme 2 Synthesis of BBPs by ClAc ligation at the example of 27c.
One letter codes are used for amino acids, upper case letters ¼ L-
amino acids, lower case letters ¼ D-amino acids, italics ¼ branching
amino acids, z ¼ branching D-g-thia-homoglutamate, arrow bonds
indicate peptide bonds in C/N direction. Conditions: (a) Fmoc SPPS;
(b) Pd(PPh3)4, PhSiH3, anh. CH2Cl2; (c) HATU, iPr2EtN, NMP–DMSO
4 : 1; (d) piperidine–DMF 1 : 4; (e) (ClCH2CO)2O, CH2Cl2; (f)
CF3CO2H–iPr3SiH–H2O 94 : 5 : 1; (g) KI, iPr2EtN, CH3CN–H2O 1 : 1.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinecontained glycine as an acyclic peptide portion, which was
extended with the photoreactive benzoylphenylalanine in the
photoreactive probes 27x–29x or simply phenylalanine their
non-photoreactive analogs 27s–29s followed by a glycyl-glycine
spacer and a biotinylated lysine (Fig. 6A and Table 3). The
structure of BBP 27c was determined by NMR and showed a
compact bicyclic structure stabilized by intramolecular
hydrogen bonds with a molecular shape comparable to a short
stretch of an a-helix structure, presumably a favourable
arrangement for protein binding (Fig. 6B). As for other nor-
bornapeptides the CD spectrum of 27c was unchanged in the
presence of folding inducers or denaturants, suggesting
conformational stability (Fig. 6C). The ability of the bio-
tinylated probes 27x/s–29x/s to bind to streptavidin was
conrmed in a colorimetric HABA (40-hydroxyazobenzene-2-
carboxylic acid) displacement assay.
Incubation of the photoreactive BBPs 27x–29x with a HeLa
cell lysate under UV irradiation removed over 90% of the
compounds from solution, while the non-photoreactive 27s–29s
and the parent BBP 27c–29c were unaﬀected under the same
conditions (Fig. 6D). Furthermore, the photoreactive BBPs 27x–Chem. Sci., 2015, 6, 5473–5490 | 5479
Fig. 6 Identiﬁcation of BBP protein binders. (A). Structure of the tested BBP. (B). Structure of 27c determined by NMR. (C). Circular dichroism
spectrumof 27c in aq. 10mMphosphate buﬀer pH¼ 7.0 (black), in 25% triﬂuoroethanol in aq. 10mMphosphate buﬀer pH¼ 7.0 (red), and in aq. 6
M guanidinium chloride (blue). (D). Percentage of BBP 27x/s/c detected by LC/MS of supernatant after incubation and centrifugation. Control ¼
cell culture medium, 1 h, 4 C; HeLa ¼ HeLa cell lysate, 1 h, 37 C; denat. HeLa ¼ heat denaturated HeLa cell lysate, 1 h, 37 C; HeLa + UV: HeLa
cell lysate, irradiation with UV 310 nm for 10 min. Results were similar with 28x/s/c and 29x/s/c (data not shown) (E). Targets identiﬁed by CCMS.
(F). MicroScale Thermophoresis of 27c with CALM1 (calmodulin). (G). Isothermal titration calorimetry of 27c with CALM1.
Table 3 Synthesis of BBP for CCMS experiments
No. Length Sequencea mg Yieldb (%) [M + H]+ calc./obs.c
27c 8 K2E1Kwz2WK1G 19.0 11 1085.53/1085.52
27x 12 K2E1Kwz2WK1GBGGK(biot) 12.0 5 1804.85/1804.48
27s 12 K2E1Kwz2WK1GFGGK(biot) 12.3 5 1700.82/1700.47
28c 8 R2E1Rfz2FK1G 5.1 3 1063.52/1063.52
28x 12 R2E1Rfz2FK1GBGGK(biot) 7.9 3 892.42/892.42 (z ¼ 2)
28s 12 R2E1Rfz2FK1GFGGK(biot) 10.5 4 839.91/840.50 (z ¼ 2)
29c 8 E2E1Efz2FK1G 1.2 1 1009.41/1009.41
29x 12 E2E1Efz2FK1GBGGK(biot) 3.0 1 864.86/864.86 (z ¼ 2)
29s 12 E2E1Efz2FK1GFGGK(biot) 8.4 4 1624.69/1624.27
a BBP sequences as SMILES-like strings: superscript numbers indicate couple of residues involved in the rst, second cyclization reactions. The C-
termini are carboxamides CONH2. B ¼ benzoylphenylalanine, K(Biot) ¼ side-chain biotinylate lysine, z ¼ branching g-thia-homoglutamic acid.
b Yields are given as total yields (SPPS and second thioether ligation). In all cases, yields are calculated for the corresponding triuoroacetate
salts. c ESI-MS positive mode spectra were recorded on a LTQ OrbitrapXL hybrid ion trap-Orbitrap mass spectrometer.
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View Article Online29x were unaﬀected without UV-irradiation, or with UV irradi-
ation in buﬀer only, or with UV irradiation in presence of a
thermally denatured HeLa cell lysate, indicating a specic cross-5480 | Chem. Sci., 2015, 6, 5473–5490linking reactivity with protein components of the HeLa cell
lysate. The CCMS experiment was carried by incubating HeLa
cell lysates for 1 h at 4 C with the photoreactive BBPs (27x–29x,This journal is © The Royal Society of Chemistry 2015
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View Article Online5 mM) or the unreactive phenylalanine analogs (27s–29s, 5 mM)
with or without excess of the parent BBP as competitor (27c–29c,
240 mM), followed by a 10 min irradiation at 310 nm to allow for
photo-cross-linking. The cross-linked products were then
collected on streptavidin-coated magnetic beads, and analyzed
by on-bead trypsin digestion followed by LC-MSn. MS data were
analysed using MaxQuant33 using the human database from
UniProtKB/Swiss-prot.21b
Focusing on proteins identied by at least two peptides with
>99% condence and signicantly enriched in the x over x + c
or in s over s + c experiments (>2-fold, triplicate experiments)
revealed several potential protein binders for each of the three
BBPs (Fig. 6E). Among the various hits, CALM1 (calmodulin)
stood out as being specically targeted by both 27x and 27s,
suggesting that a covalent cross-link was not necessary.
Furthermore, the related 28x or 28s with arginines replacing
the lysine and phenylalanines replacing tryptophans did not
indicate this target, suggesting specicity. The binding of 27c
to calmodulin was therefore investigated closer despite the fact
that this protein is a relatively abundant component of the cell
and a frequent hit in proteomics experiments. To test whether
27c bound to calmodulin, the binding aﬃnity was determined
by microscale thermophoresis (MST, Fig. 6F).34 Indeed 27c
bound calmodulin with good aﬃnity (KD ¼ 4.5  1.1 mM).
There was no measurable aﬃnity for analog 28c with arginine
replacing lysines and phenylalanines replacing tryptophans,
showing that binding was sequence specic, in line with the
CCMS results where calmodulin was only indicated as a hit for
27c. The measured aﬃnity of 27c was further conrmed by
isothermal titration calorimetry (Fig. 6G), which gave a
stronger binding aﬃnity of KD ¼ 0.80  0.05 mM. Binding was
unchanged in the presence of excess Ca2+, but was reduced 25-
fold in the presence of EDTA, indicating that 27c interacted
preferentially with calcium-bound calmodulin. The weaker
binding observed by MST might reect the much lower protein
concentration used in MST (10 nM vs. 50 mM by ITC), or a
perturbation by the uorescence label coupled to calmodulin.
ITC also indicated weak binding by analog BBP 28c (KD ¼ 6.8 
0.6 mM).Fig. 7 Human serum stability assays on norbornapeptide 27c, 15 and
its monocyclic and linear analogs.
This journal is © The Royal Society of Chemistry 2015Although the complex of calmodulin with 27c did not yield to
crystallization, we speculate that 27c interacts with calmodulin
by mimicking part of the a-helical IQ-motifs ((I/L/V)
QXXXRXXXX(R/K)) found in the cardiac Cav1.2 calcium channel
binding with Ca2+-calmodulin.35 Although the 27c consists of
only eight residues, it contains sequence components compa-
rable to the IQ motif. One of the tryptophans in 27cmight work
as the rst hydrophobic residue in IQmotif, while its C-terminal
glycine amide could act similarly to the adjacent glutamine in
the IQ motif. The two lysines might engage in further hydro-
philic interactions and the remaining tryptophan can
contribute more hydrophobicity.
Pharmacokinetics
Peptides generally suﬀer from rapid degradation by proteolysis
in serum, and poor membrane permeability, which limits their
use as drugs. The constrained nature of BBPs such as 27c
should limit sensitivity towards proteolysis. Indeed BBP 27c was
entirely stable upon incubation in human serum for 24 h at 37
C. The same observation was made with several other BBPs
including 15, in which case the mono-cyclic analog obtained
during synthesis was also stable, while its linear precursor was
degraded (Fig. 7).
On the other hand BBPs showed the typical limitation of
peptides in terms of membrane permeability when tested in a
parallel articial membrane permeation assay (PAMPA),36 with
no measurable permeation through the membrane in compar-
ison to the control peptide cyclosporine (data not shown).
Cyclosporine is a cyclic peptide where all peptide bonds are N-
methylated, which makes this compound much more hydro-
phobic than peptides bearing NH groups on their amides.
Clearly, the formation of several intramolecular hydrogen
bonds in BBPs was not suﬃcient to obtain signicant
membrane permeability. The possibility to increase BBP
membrane permeation by N-methylation, in particular of
backbone amide groups exposed to solvents25a,37 was investi-
gated in the case of the water insoluble BBP 1, focusing on the
N-methylation of its solvent-exposed backbone amide at resi-
dues 1, 2 and 4. Single and double N-methyl derivatives 30–35
were obtained by attaching the N-methyl group at various
positions during SPPS (Table 4).6 A crystal structure was
obtained in the case of 32 showing that N-methylation did not
aﬀect the scaﬀold geometry and conrming methylation of a
solvent exposed NH group (Fig. 8). However, none of these N-
methylated BBP analogs showed measurable PAMPA
permeability.Table 4 Synthesis and yield for N-methylated norbornapeptides
BBP Sequence mg Yield (%) [M + H]+ calc.
30 Mel
1Gk2fPE1a2 2.2 1 739.41/739.41
31 l1MeGk
2fPE1a2 6.2 3 739.41/739.41
32 l1Gk2MefPE
1a2 4.3 2 739.41/739.41
33 Mel
1
MeGk
2fPE1a2 11.5 5 753.43/753.43
34 Mel
1Gk2MefPE
1a2 13.2 5 753.43/753.43
35 l1MeGk
2
MefPE
1a2 11.1 5 753.43/753.43
Chem. Sci., 2015, 6, 5473–5490 | 5481
Fig. 8 Crystal structure of 32 (purple), superimposed with 10 (yellow).
Frame: detail of the orientation of the aromatic ring, tilted by the
presence of the N-methyl group in 32.
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View Article OnlineConclusion
The experiments described above tested the potential of bridged
bicyclic peptides (BBP) as a new type of scaﬀold for peptide-
based drug design. A structural study focusing on norborna-
peptides using X-ray crystallography, NMR and CD spectroscopy
showed that BBP are rigid scaﬀolds for the display of amino acid
side chains, however their precise geometry is inuenced in non-
trivial manner by residue stereochemistry. Selected dipeptide
loops of the BBPmimic b-turns, while triplets of side-chainsmay
adopt relative orientations comparable to those in a-helices. A
proteomics based screening using capture compound mass
spectrometry (CCMS) was used to identify 27c as a binder for
calmodulin, thus providing a proof-of-principle example that
BBPs as small as norbornapeptide can show specic protein
binding. This and other BBPs showed high stability towards
serum proteolytic degradation. Future experiments will address
the systematic exploration of BBP as protein binders.Experimental section
Materials and reagents
All reagents were purchased either from Sigma Aldrich (St.
Louis, MO, USA), Acros Organics (Thermo Fisher, Geel, Bel-
gium) or Fluorochem (Hadeld, UK). Resins, coupling agents,
amino acids and their derivatives were purchased from
Advanced ChemTech (Louisville, KY, USA), Polypeptide Labo-
ratories (Strasbourg, France), Iris Biotech (Marktredwitz, Ger-
many), GLS Biochem (Shanghai, China), Rapp Polymere
(Tu¨bingen, Germany) or Novabiochem (Merck Biosciences,
La¨ufelngen, Switzerland).Analytics
Analytical RP-HPLC was performed with an Ultimate 3000
Rapid Separation LC System (DAD-3000RS diode array detector)5482 | Chem. Sci., 2015, 6, 5473–5490using an Acclaim RSLC 120 C18 column (2.2 mm, 120 A˚, 3  50
mm, ow 1.2 mL min1) from Dionex (Sunnyvale, CA, USA).
Data recording and processing was done with Dionex Chro-
meleon Management System (version 6.80). Preparative RP-
HPLC was performed with a Waters Prep LC Controller System
using a Dr. Maisch GmbH Reprospher column (C18-DE, 100 
30 mm, particle size 5 mm, pore size 100 A˚, ow rate 40 mL
min1). Compounds were detected by UV absorption at 214 nm
using aWaters 486 Tunable Absorbance Detector. The following
eluents were used for all RP-HPLC measurements: “A” (Milli-Q
deionized H2O with 0.1% TFA); “D” (Milli-Q deionized H2O–
HPLC-grade acetonitrile (10 : 90) with 0.1% TFA). LC-MS data
were collected aer coupling the analytical system described
above with a LCQ Fleet Ion Trap mass spectrometer (Thermo
Scientic, San Jose, CA, USA). LC-MS data recording and pro-
cessing was done with Xcalibur (version 2.2, Thermo Scientic).
High resolution MS spectra, recorded on a LTQ OrbitrapXL
Hybrid Ion Trap-Orbitrap mass spectrometer (Thermo Scien-
tic), were provided by the analytical service of the Department
of Chemistry and Biochemistry at the University of Bern (group
P.D. Dr. Stefan Schu¨rch).Synthesis of monocyclic peptides on Wang resin
Peptide syntheses were performed manually in 10 mL poly-
propylene syringes (B. Braun, Melsungen, Germany) equipped
with a polyethylene frit, a Teon stopcock and stopper. DCM,
NMP and MeOH were purchased in technical grade and used
without prior distillation. Stirring of the reaction mixture at any
given step described below was performed by attaching the
closed syringe to a rotating axis. Wang resins pre-loaded with
one amino acid were swollen in DCM for 10 min prior the start
of the synthesis. At each step the Fmoc protecting group was
removed with 6 mL of DMF–piperidine (4 : 1) for 10 min. Aer
ltration the procedure was repeated and nally the resin was
washed (2 each) with NMP, MeOH and DCM. For coupling, 3
eq. of Fmoc-protected amino acid, 3 eq. of PyBOP in 6 mL of
NMP were added to the resin. 6 eq. of DIPEA were added and the
reaction was stirred for 60 min (reaction times were prolonged
to 120min for couplings of bridgehead amino acids, which were
performed with 2 eq. of both Fmoc-protected amino acid and
HATU as coupling agent). The resin was then washed (2 each)
with NMP, MeOH and DCM. Aer the last coupling, the poly-
propylene syringe was equipped with a septum and dried under
vacuum for one hour. It was then swollen in dry DCM for 15 min
under argon. To remove the allyl protecting group, solvent was
removed, Pd(PPh3)4 (0.20 eq.) was dissolved in 6 mL of dry DCM
and added to the resin under argon. Phenylsilane (20 eq.) was
then added to the resin. The reaction was stirred under argon
bubbling for 45 min. The reagents were then removed by
ltration and the resin washed with DCM (6 mL, 2  15 min)
and sodium diethylamino dithiocarboxylate (20 mM in DMF, 6
mL, 15 min). The last Fmoc protecting group was then removed
as above. On resin cyclization was performed using HATU (3 eq.)
and DIPEA (6 eq.) were added to the peptidyl-resins in 6 mL of
NMP–DMSO (4 : 1) and the mixtures were stirred at room
temperature for 2–6 h. The reagents were removed by ltrationThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineand the resins washed (2 each) with NMP, MeOH and DCM.
The TNBS test was used to check the eﬀectiveness of the cycli-
zations: if deemed necessary, the cyclization step was repeated.
Cleavage was carried out by treating the resins with 6 mL of a
TFA–TIPS–H2O (95 : 4 : 1) solution for 2 h. The peptide solu-
tions were separated from the resin by ltration, evaporated and
dried under high vacuum. The crudes were then dissolved in a
H2O–CH3CN mixture, puried by preparative RP-HPLC and
lyophilized again. Yields were calculated for the triuoroacetate
salts of the products.
Synthesis of monocyclic peptides with Boc-protected side-
chains on 2CT resin
Monocyclic peptides were synthesized on 2-chlorotrityl resin
(0.68–1.63 mmol g1). Elongation of the peptides by Fmoc SPPS,
allyl ester deprotection and intramolecular cyclization were
carried out with the same procedures described above on Wang
resin. If the rst amino acid was pre-loaded on the resin, the
synthesis started with the coupling of the next amino acid.
Otherwise, to load the rst residue 2-chlorotrityl chloride resin
was swollen in dry DCM for 10min and the solvent was removed
by ltration. 5 eq. of Fmoc-protected amino acid and 6 eq.
DIPEA were dissolved in dry DCM (6mL) and added to the resin.
The reactions were stirred for 6–10 h at r.t., and the solution was
removed by ltration. The resin was washed with DCM and then
treated with DCM–MeOH–DIPEA (4 : 1 : 0.2) for 30 min, to
saturate eventual unreacted chloride sites. The resin was then
washed with NMP–MeOH–DCM (2 each) and the rst Fmoc
deprotection was performed. Aer SPPS and on-resin cycliza-
tion as above, cleavage was carried out by treating the resins
with 6 mL of a AcOH–TFE–DCM (1 : 2 : 7) solution for 2 h. The
peptide solutions were separated from the resin by ltration,
evaporated and dried under high vacuum. To remove the Mtt
protecting group, the product was redissolved in DCM (15 mL),
TFA (150 mL) was added dropwise under stirring at r.t. (the
solutions turned bright yellow). Reactions were monitored by
RP-HPLC until complete disappearance of the starting mate-
rials. Aer 21 h the reactions were stopped by adding DIPEA
(350 mL) and removing the solvent by evaporation. Alternatively
cleavage and Mtt deprotection were carried out simultaneously
by drying the resin under high vacuum for 2 h and then treating
with consecutive batches of TFA–TIPS–DCM (1 : 0.5 : 98.5) (5
mL, 10 min, 5–7). Aer the rst 1–2 acidic treatments, the
resins turn dark. The solutions were collected, neutralized with
a slight excess of DIPEA and evaporated.
Second cyclization
Bicyclic peptides were synthesized by subjecting monocyclic
peptides to amide bond formation conditions in high dilution
(0.5–1mM). To a solution of PyBOP or HATU (3 eq.) and DIPEA (6
eq.) in DCM–DMF (20 : 1), a 5–10 mM solution of monocyclic
peptide in DMF was slowly added dropwise at r.t. under
vigorous stirring. The reaction was le stirring for 2 h at r.t. and
monitored via RP-HPLC, until complete disappearance of the
starting material. The reaction was then quenched by evapora-
tion of the solvent. For the 2CT resin products, side chainThis journal is © The Royal Society of Chemistry 2015protecting groups were removed as follows: the product was
dissolved in CHCl3 (20 mL) and washed 3 with a saturated
solution of KHSO4 and 1 with H2O; the organic phases were
collected, dried over anhydrous Na2SO4 and evaporated. Then 8
mL of TFA–DCM (4 : 1) +0.1% TIPS was added to the remainder
and the reactions were stirred at r.t. for 2 h. In both procedures,
the crude was nally dissolved in a H2O–CH3CN mixture,
puried by preparative RP-HPLC and lyophilized. Yields were
calculated by considering the triuoroacetate salts of mono-
cyclic peptides as starting material.
Synthesis using thioether ligation
BBPs 27–29 were synthesized by standard Fmoc-SPPS on Ten-
taGel S RAM resin. Elongation of the sequences, Allyl/Alloc
deprotection and the rst on resin cyclization were carried out
with the previously described procedures. The N-terminus was
then chloroacetylated aer the nal Fmoc removal by treating
the resin for 30 min with a solution of chloroacetic anhydride
(10 eq.) in DCM (6 mL per syringe). The procedure was repeated
once. The cleavage was then carried out by treating the resins
with 6 mL of a TFA–TIPS–DODT–H2O (94 : 2.5 : 2.5 : 1) solution
for 1 h or, alternatively, with a TFA–TIPS–H2O (95 : 4 : 1) solu-
tion previously purged with Ar (10 min). The peptide solutions
were separated from the resin by ltration, evaporated and
dried under high vacuum. The remainder was then redissolved
in A and washed once with EA in a 100 mL separation funnel.
The aqueous phase was then lyophilized. The eﬀectiveness of
the washing step was monitored by analytical RP-HPLC. The
resulting crude monocyclic peptides were then subjected to
thioether ligation conditions in high dilution. Potassium iodide
(20 eq.) and DIPEA (50 eq.) were dissolved in 100 mL of H2O–
CH3CN (1 : 1) and the solutions were purged with Ar for 10 min.
N-term chloroacetylated monocyclic peptide crudes were dis-
solved in 5 mL of H2O–CH3CN (1 : 1), the solutions purged with
Ar for 10 minutes and nally added dropwise to the rst solu-
tion. The reactions were le under stirring at r.t. until complete
disappearance of the starting material, as revealed by analytical
RP-HPLC. The mixtures were then ash-frozen, lyophilized and
puried by preparative RP-HPLC. Yields were calculated on
triuoroacetate salts of bicyclic peptides and by considering
triuoroacetate salts of monocyclic peptides as starting
material.
Synthesis of N-methylated BBPs
N-Methylated BBPs were prepared using Fmoc synthesis
procedure on 2CT resin described above. N-Methylation was
performed following the literature procedure6 at the desired
position aer Fmoc removal. The resin was treated with o-NBS
and collidine and rotated for 30 minutes then washed with
DCM. ForN-methylation, DBU and NMPwere added to the resin
followed by dimethyl sulfate and the syringe rotated for 8
minutes then washed with DCM. For o-NBS deprotection, DBU
and mercaptoethanol were added and rotated for 10 minutes.
Then the resin was washed using NMP, Methanol and DCM.
The chloranil test was used to follow the release of the N-
methylated amine.Chem. Sci., 2015, 6, 5473–5490 | 5483
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View Article Onlinel1GkfPE1a (1-mono). From Fmoc-D-Ala-Wang resin (400 mg,
0.44 mmol g1), 1-mono was obtained as foamy white solid aer
preparative RP-HPLC (50.6 mg, 59.1 mmol, 34%). Analytical RP-
HPLC: tR ¼ 3.148 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
l1Gk2fPE1a2 (1). Starting from 1-mono (50.6 mg, 59.1 mmol), 1
was obtained as foamy white solid aer preparative RP-HPLC
(34.9 mg, 48.1 mmol, 82%). Analytical RP-HPLC: tR ¼ 3.31 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38 [M
+ Na]+. 1H-NMR assignment available in electronic format.
l1GkfPE1A (2-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 2-mono was obtained as foamy white solid aer
preparative RP-HPLC (37.1 mg, 43.3 mmol, 25%). Analytical RP-
HPLC: tR ¼ 3.12 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
l1Gk2fPE1A2 (2). Starting from 2-mono (37.1 mg, 43.3 mmol), 2
was obtained as foamy white solid aer preparative RP-HPLC
(25.9 mg, 29.5 mmol, 60%). Analytical RP-HPLC: tR ¼ 3.31 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+. 1H-NMR assignment available in electronic format.
l1GkFPE1a (3-mono). From Fmoc-D-Ala-Wang resin (400 mg,
0.44 mmol g1), 3-mono was obtained as foamy white solid aer
preparative RP-HPLC (23.9 mg, 27.9 mmol, 16%). Analytical RP-
HPLC: tR ¼ 3.22 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
l1Gk2FPE1a2 (3). Starting from 3-mono (23.9 mg, 27.9 mmol), 3
was obtained as foamy white solid aer preparative RP-HPLC
(11.4 mg, 15.7 mmol, 56%). Analytical RP-HPLC: tR ¼ 3.52 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.
L1GkfPE1a (4-mono). From Fmoc-D-Ala-Wang resin (400 mg,
0.44 mmol g1), 4-mono was obtained as foamy white solid aer
preparative RP-HPLC (62.7 mg, 73.2 mmol, 42%). Analytical RP-
HPLC: tR ¼ 3.20 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
L1Gk2fPE1a2 (4). Starting from 4-mono (62.7 mg, 73.2 mmol), 4
was obtained as foamy white solid aer preparative RP-HPLC
(35.2 mg, 48.6 mmol, 66%). Analytical RP-HPLC: tR ¼ 3.51 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.
l1GkFPE1A (5-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 5-mono was obtained as foamy white solid aer
preparative RP-HPLC (17.2 mg, 20.1 mmol, 12%). Analytical RP-
HPLC: tR ¼ 3.01 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
l1Gk2FPE1A2 (5). Starting from 5-mono (17.2 mg, 20.1 mmol), 5
was obtained as foamy white solid aer preparative RP-HPLC
(8.6 mg, 11.9 mmol, 59%). Analytical RP-HPLC: tR¼ 3.03 min (A/
D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.5484 | Chem. Sci., 2015, 6, 5473–5490L1GkfPE1A (6-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 6-mono was obtained as foamy white solid aer
preparative RP-HPLC (43.5 mg, 50.8 mmol, 30%). Analytical RP-
HPLC: tR ¼ 2.92 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
L1Gk2fPE1A2 (6). Starting from 6-mono (43.5 mg, 50.8 mmol),
6 was obtained as foamy white solid aer preparative RP-HPLC
(22.4 mg, 30.9 mmol, 61%). Analytical RP-HPLC: tR ¼ 3.38 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.
L1GkFPE1a (7-mono). From Fmoc-D-Ala-Wang resin (400 mg,
0.44 mmol g1), 7-mono was obtained as foamy white solid aer
preparative RP-HPLC (58.1 mg, 67.8 mmol, 39%). Analytical RP-
HPLC: tR ¼ 3.13 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
L1Gk2FPE1a2 (7). Starting from 7-mono (58.1 mg, 67.8 mmol),
7 was obtained as foamy white solid aer preparative RP-HPLC
(17.5 mg, 24.1 mmol, 36%). Analytical RP-HPLC: tR ¼ 3.47 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.
L1GkFPE1A (8-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 8-mono was obtained as foamy white solid aer
preparative RP-HPLC (55.6 mg, 64.9 mmol, 38%). Analytical RP-
HPLC: tR ¼ 2.86 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
L1Gk2FPE1A2 (8). Starting from 8-mono (50.2 mg, 59.1 mmol),
8 was obtained as foamy white solid aer preparative RP-HPLC
(34.3 mg, 47.3 mmol, 81%). Analytical RP-HPLC: tR ¼ 3.34 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H52N8O8 calc./obs. 725.40/725.40 [M + H]
+, 747.38/747.38
[M + Na]+.
L1GKFPE1A (9-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 9-mono was obtained as foamy white solid aer
preparative RP-HPLC (43.5 mg, 59.1 mmol, 30%). Analytical RP-
HPLC: tR ¼ 3.17 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C36H54N8O9 calc./obs. 743.41/743.41 [M + H]
+.
L1GK2FPE1A2 (9). Starting from 9-mono (28.9 mg, 33.7 mmol),
9 was obtained as foamy white solid aer preparative RP-HPLC
(6.6 mg, 9.1 mmol, 27%). Analytical RP-HPLC: tR¼ 2.98 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C36H52N8O8
calc./obs. 725.40/725.40 [M + H]+, 747.38/747.38 [M + Na]+.
l1Gk2yPE1a2 (10). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
10 was obtained as foamy white solid aer preparative RP-HPLC
(8.9 mg, 12.0 mmol, 4%). Analytical RP-HPLC: tR¼ 2.87 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C36H52N8O9
calc./obs. 741.39/741.39 [M + H]+, 763.37/763.37 [M + Na]+,
779.35/779.35 [M + K]+, 390.17/390.17 [M + K + H]2+.
l1GkyPE1A (11-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 11-mono was obtained as foamy white solid
aer preparative RP-HPLC (22.9 mg, 26.2 mmol, 26%). Analytical
RP-HPLC: tR ¼ 2.58 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.45
[M + H]+.This journal is © The Royal Society of Chemistry 2015
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View Article Onlinel1Gk2yPE1A2 (11). Starting from 11-mono (21.7 mg, 24.9
mmol), 11 was obtained as foamy white solid aer preparative
RP-HPLC (10.9 mg, 14.7 mmol, 59%). Analytical RP-HPLC: tR ¼
2.79 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.42 [M + H]
+.
l1GkYPE1a (12-mono). From Fmoc-D-Ala-Wang resin (300 mg,
0.44 mmol g1), 12-mono was obtained as foamy white solid
aer preparative RP-HPLC (16.3 mg, 18.7 mmol, 12%). Analytical
RP-HPLC: tR ¼ 2.66 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.64
[M + H]+.
l1Gk2YPE1a2 (12). Starting from 12-mono (15.1 mg, 17.3
mmol), 12 was obtained as foamy white solid aer preparative
RP-HPLC (4.7 mg, 6.3 mmol, 37%). Analytical RP-HPLC: tR ¼
2.97 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.42 [M + H]
+.
L1GkyPE1a (13-mono). From Fmoc-D-Ala-Wang resin (300mg,
0.44 mmol g1), 13-mono was obtained as foamy white solid
aer preparative RP-HPLC (36.8 mg, 42.2 mmol, 28%). Analytical
RP-HPLC: tR ¼ 2.58 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.48
[M + H]+.
L1Gk2yPE1a2 (13). Starting from 13-mono (35.0 mg, 40.1
mmol), 13 was obtained as foamy white solid aer preparative
RP-HPLC (21.8 mg, 29.4 mmol, 73%). Analytical RP-HPLC: tR ¼
2.91 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.40 [M + H]
+.
l1GkYPE1A (14-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 14-mono was obtained as foamy white solid
aer preparative RP-HPLC (18.3 mg, 21.0 mmol, 14%). Analytical
RP-HPLC: tR ¼ 2.56 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.68
[M + H]+.
l1Gk2YPE1A2 (14). Starting from 14-mono (17.0 mg, 19.5
mmol), 14 was obtained as foamy white solid aer preparative
RP-HPLC (7.0 mg, 9.5 mmol, 49%). Analytical RP-HPLC: tR ¼
2.74 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.43 [M + H]
+.
L1Gky(tBu)PE
1A (15-mono). From H-L-Ala-2CT resin (350 mg,
0.68 mmol g1), 15-mono was obtained as foamy white solid
aer preparative RP-HPLC (60.7 mg, 65.3 mmol, 28%). Analytical
RP-HPLC: tR ¼ 3.67 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C40H62N8O10 calc./obs. 815.47/815.47
[M + H]+.
L1Gk2yPE1A2 (15). Starting from 15-mono (60.7 mg, 65.3
mmol), 15 was obtained as foamy white solid aer preparative
RP-HPLC (20.5 mg, 27.7 mmol, 42%). Analytical RP-HPLC: tR ¼
3.02 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O9 calc./obs. 741.39/741.39 [M + H]
+, 763.37/
763.37 [M + Na]+.
L1GkYPE1a (16-mono). From Fmoc-D-Ala-Wang resin (300
mg, 0.44 mmol g1), 16-mono was obtained as foamy white solid
aer preparative RP-HPLC (45.4 mg, 52.0 mmol, 35%). Analytical
RP-HPLC: tR ¼ 2.53 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.48
[M + H]+.This journal is © The Royal Society of Chemistry 2015L1Gk2YPE1a2 (16). Starting from 16-mono (29.7 mg, 34.0
mmol), 16 was obtained as foamy white solid aer preparative
RP-HPLC (18.1 mg, 24.4 mmol, 72%). Analytical RP-HPLC: tR ¼
2.93 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.41 [M + H]
+.
L1GkYPE1A (17-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 17-mono was obtained as foamy white solid
aer preparative RP-HPLC (58.6 mg, 67.1 mmol, 45%). Analytical
RP-HPLC: tR ¼ 2.48 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.49
[M + H]+.
L1Gk2YPE1A2 (17). Starting from 17-mono (56.8 mg, 65.1
mmol), 17 was obtained as foamy white solid aer preparative
RP-HPLC (7.3 mg, 9.9 mmol, 15%). Analytical RP-HPLC: tR ¼
2.87 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.45 [M + H]
+.
L1GKYPE1A (18-mono). From Fmoc-Ala-Wang resin (300 mg,
0.57 mmol g1), 18-mono was obtained as foamy white solid
aer preparative RP-HPLC (45.7 mg, 52.3 mmol, 35%). Analytical
RP-HPLC: tR ¼ 2.66 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C36H54N8O10 calc./obs. 759.40/759.48
[M + H]+.
L1GK2YPE1A2 (18). Starting from 18-mono (43.8 mg, 50.2
mmol), 18 was obtained as foamy white solid aer preparative
RP-HPLC (13.8 mg, 18.6 mmol, 37%). Analytical RP-HPLC: tR ¼
2.72 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H52N8O8 calc./obs. 741.39/741.40 [M + H]
+.
k1Gk2fPE1a2 (19). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
19 was obtained as foamy white solid aer preparative RP-HPLC
(6.6 mg, 7.7 mmol, 2.4%). Analytical RP-HPLC: tR ¼ 2.78 min (A/
D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C36H53N9O8 calc./obs. 740.41/740.41 [M + H]
+, 762.39/762.39
[M + Na]+, 389.68/389.68 [M + K + H]2+.
l1Sk2fPE1a2 (20). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
20 was obtained as foamy white solid aer preparative RP-HPLC
(23.4 mg, 31.0 mmol, 9.5%). Analytical RP-HPLC: tR ¼ 3.18 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C37H54N8O9 calc./obs. 755.41/755.41 [M + H]
+, 777.39/777.39
[M + Na]+, 397.18/397.18 [M + K + H]2+, 793.36/793.36 [M + K]+,
389.19 [M + Na + H]2+.
l1Gk2fKE1a2 (21). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
21 was obtained as a white solid aer preparative RP-HPLC (7.7
mg, 8.9 mmol, 2.7%). Analytical RP-HPLC: tR ¼ 2.69 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C37H57N9O8
calc./obs. 756.44/756.44 [M + H]+, 778.42/778.42 [M + Na]+.
k1Gk2ePE1c2 (22). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
22 was obtained as a white solid aer preparative RP-HPLC (6.4
mg, 7.4 mmol, 2.3%). Analytical RP-HPLC: tR ¼ 1.92 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C32H51N9O10S calc./obs. 754.36/754.35 [M + H]
+, 776.34/776.34
[M + Na]+, 396.65/396.65 [M + K + H]2+.
K(Boc)
1GkfPE1A (23-mono). From H-L-Ala-2CT resin (350 mg,
0.68 mmol g1), 23-mono was obtained as foamy white solid
aer preparative RP-HPLC (32.7 mg, 33.6 mmol, 14%). Analytical
RP-HPLC: tR ¼ 3.53 min (A/D 100 : 0 to 0 : 100 in 7.5 min,Chem. Sci., 2015, 6, 5473–5490 | 5485
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View Article Onlinel ¼ 214 nm). MS (ESI+): C41H63N9O11 calc./obs. 858.47/858.47
[M + H]+.
K1Gk2fPE1A2 (23). Starting from 23-mono (32.7 mg, 33.6
mmol), 23 was obtained as glassy white solid aer preparative
RP-HPLC (15.0 mg, 17.6 mmol, 52%). Analytical RP-HPLC: tR ¼
2.64 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS
(ESI+): C36H53N9O8 calc./obs. 740.41/740.41 [M + H]
+, 370.71/
370.71 [M+2H]2+.
L1Sk2fPE1A2 (24). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
24 was obtained as foamy white solid aer preparative RP-HPLC
(12.2 mg, 16.2 mmol, 6%). Analytical RP-HPLC: tR¼ 3.16 min (A/
D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C37H54N8O9 calc./obs. 755.41/755.41 [M + H]
+, 777.39/777.39
[M + Na]+.
L1Gk2fKE1A2 (25). From 2CT-Cl resin (200 mg, 1.3 mmol g1)
25 was obtained as foamy white solid aer preparative RP-HPLC
(12.0 mg, 16.2 mmol, 5%). Analytical RP-HPLC: tR¼ 2.56 min (A/
D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C37H57N9O8 calc./obs. 756.44/756.44 [M + H]
+, 778.42/778.42
[M + Na]+.
K1Gk2ePE1C2 (26). From 2CT-Cl resin (200 mg, 1.3 mmol g1),
26 was obtained as foamy white solid aer preparative RP-HPLC
(5.3 mg, 6.1 mmol, 2%). Analytical RP-HPLC: tR ¼ 1.91 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C37H53N9O9
calc./obs. 754.35/754.35 [M + H]+.
K2E1Kwz2WK1G (27c). From TentaGel S RAM resin (500 mg,
0.26 mmol g1), 27c was obtained as foamy white solid aer
preparative RP-HPLC (19.0 mg, 17.5 mmol, 11%). Analytical RP-
HPLC: tR ¼ 2.78 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C52H72N14O10S calc./obs. 1085.53/1085.52
[M + H]+.
K2E1Kwz2WK1GBGGK(biot) (27x). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 27x was obtained as foamy white solid
aer preparative RP-HPLC (12.0 mg, 6.7 mmol, 5%). Analytical
RP-HPLC: tR ¼ 3.51 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C88H117N21O17S2 calc./obs. 1804.85/1804.48
[M + H]+.
K2E1Kwz2WK1GFGGK(biot) (27s). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 27s was obtained as foamy white solid
aer preparative RP-HPLC (12.3 mg, 7.2 mmol, 5%). Analytical
RP-HPLC: tR ¼ 3.22 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C81H113N21O16S2 calc./obs. 1700.82/1700.47
[M + H]+.
R2E1Rfz2FK1G (28c). From TentaGel S RAM resin (500 mg,
0.26 mmol g1), 29c was obtained as foamy white solid aer
preparative RP-HPLC (5.1 mg, 4.8 mmol, 3%). Analytical RP-
HPLC: tR ¼ 2.75 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C48H70N16O10S calc./obs. 1063.52/1063.52
[M + H]+.
R2E1Rfz2FK1GBGGK(biot) (28x). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 29x was obtained as foamy white solid
aer preparative RP-HPLC (7.9 mg, 4.4 mmol, 3%). Analytical
RP-HPLC: tR ¼ 3.59 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C84H115N23O17S2 calc./obs. 892.42/892.42
[M + 2H]2+.
R2E1Rfz2FK1GFGGK(biot) (28s). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 29s was obtained as foamy white solid5486 | Chem. Sci., 2015, 6, 5473–5490aer preparative RP-HPLC (10.5 mg, 6.3 mmol, 4%). Analytical
RP-HPLC: tR ¼ 3.20 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C77H111N23O16S2 calc./obs. 839.91/840.50
[M + 2H]2+.
E2E1Efz2FK1G (29c). From TentaGel S RAM resin (500 mg,
0.26 mmol g1), 28c was obtained as glassy white solid aer
preparative RP-HPLC (1.2 mg, 1.2 mmol, 1%). Analytical RP-
HPLC: tR ¼ 3.16 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214
nm). MS (ESI+): C46H60N10O14S calc./obs. 1009.41/1009.41
[M + H]+.
E2E1Efz2FK1GBGGK(biot) (29x). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 28x was obtained as glassy white solid
aer preparative RP-HPLC (3.0 mg, 1.7 mmol, 1%). Analytical
RP-HPLC: tR ¼ 3.94 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C82H105N17O21S2 calc./obs. 864.86/864.86
[M + 2H]2+.
E2E1Efz2FK1GFGGK(biot) (29s). From TentaGel S RAM resin
(500 mg, 0.26 mmol g1), 28s was obtained as glassy white solid
aer preparative RP-HPLC (8.4 mg, 5.2 mmol, 4%). Analytical
RP-HPLC: tR ¼ 3.59 min (A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼
214 nm). MS (ESI+): C75H101N17O20S2 calc./obs. 1624.69/1624.27
[M + H]+.
Mel
1Gk2fPE1a2 (30). From CT resin (200 mg, 1.63 mmol g1),
30 was obtained as yellow solid aer preparative RP-HPLC (2.2
mg, 2.9 mmol, 1%). Analytical RP-HPLC: tR ¼ 3.610 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C37H54N8O8
calc./obs. 739.41/739.41 [M + H]+.
l1MeGk
2fPE1a2 (31). From CT resin (200 mg, 1.63 mmol g1),
31 was obtained as yellow solid aer preparative RP-HPLC (6.2
mg, 8.4 mmol, 3%). Analytical RP-HPLC: tR ¼ 3.595 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C37H54N8O8
calc./obs. 739.41/739.41 [M + H]+.
l1Gk2MefPE
1a2 (32). From CT resin (200 mg, 1.63 mmol g1),
32 was obtained as yellow solid aer preparative RP-HPLC (4.3
mg, 5.8 mmol, 2%). Analytical RP-HPLC: tR ¼ 3.587 min (A/D
100 : 0 to 0 : 100 in 7.5 min, l¼ 214 nm). MS (ESI+): C37H54N8O9
calc./obs. 739.41/739.41 [M + H]+.
Mel
1
MeGk
2fPE1a2 (33). FromCT resin (200mg, 1.63mmol g1),
33 was obtained as yellow solid aer preparative RP-HPLC
(11.5 mg, 15.3 mmol, 5%). Analytical RP-HPLC: tR ¼ 3.880 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C38H56N8O8 cal./obs. 753.43/753.43 [M + H]
+.
Mel
1Gk2MefPE
1a2 (34). FromCT resin (200mg, 1.63mmol g1),
34 was obtained as yellow solid aer preparative RP-HPLC
(11 mg, 14.6 mmol, 4.5%). Analytical RP-HPLC: tR ¼ 3.765 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C38H56N8O8 calc./obs. 753.43/753.43 [M + H]
+.
l1MeGk
2
MefPE
1a2 (35). FromCT resin (200mg, 1.63mmol g1),
35 was obtained as yellow solid aer preparative RP-HPLC
(13.2 mg, 17.5 mmol, 5.3%). Analytical RP-HPLC: tR ¼ 3.80 min
(A/D 100 : 0 to 0 : 100 in 7.5 min, l ¼ 214 nm). MS (ESI+):
C38H56N8O8 calc./obs. 775.41/775.41 [M + Na]
+.X-ray crystallography
All measurements were performed on an Oxford Diﬀraction
SuperNova area-detector diﬀractometer (Oxford DiﬀractionThis journal is © The Royal Society of Chemistry 2015
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View Article OnlineLtd., Yarnton, Oxfordshire, UK) using mirror optics mono-
chromated Mo Ka radiation and Al ltered.38 The unit cell
constants and an orientation matrix for data collection were
obtained from a least-squares renement of the setting angles
of reections. Data reduction was performed using CrysAlisPro
(version 1.171.34.44). The intensities were corrected for Lorentz
and polarization eﬀects, and an absorption correction based on
the multi-scan method using SCALE3 ABSPACK in CrysAlisPro
was applied. Data collection and renement parameters are
given for each crystal structure in the ESI.† The structures were
solved by direct methods using SHELXS-97, which revealed the
positions of all non-hydrogen atoms, which were rened
anisotropically. Renement of the structure was carried out on
F2 using full-matrix least-squares procedures, which minimized
the function Sw(Fo
2  Fc2)2. The weighting scheme was based
on counting statistics and included a factor to downweight the
intense reections. All calculations were performed using
SHELXL-97.†NMR studies
NMR data were acquired at a temperature of 298 K using a
Bruker AvanceII 500 MHz NMR spectrometer equipped with
an inverse dual channel (1H, X) z-gradient probehead (BBI), or
on a Bruker AvanceII 400 MHz NMR spectrometer equipped
with an inverse dual channel (1H, X) z-gradient probehead
(BBI). Proton resonances were assigned using TOCSY and
HSQC data. All NMR data were processed using TopSpin
(version 3.0). 1D 1H-NMR data were acquired with 16 to 64
transients into 32k data points over a ppm width of 12 ppm
using a W5 sequence to eliminate the water resonance.39 A
relaxation delay of 6 s was applied between transients. 2D 1H-
TOCSY and ROESY NMR data were acquired over a frequency
width of 12 ppm in both F2 and F1 into 2k complex data
points in F2 using 128 to 256 t1 increments depending on the
sample. A relaxation delay of 2 s between transients was used
for all experiments. 1H-TOCSY data were recorded using 8 or
32 transients, 1H-ROESY using 32 to 96 transients, depending
on the sample. Water suppression was achieved using a
WATERGATE routine aer the nal read pulse.40 The 2D
TOCSY NMR data were acquired with a spin-lock time of 70
ms. 2D ROESY NMR (Tr-ROESY scheme)41 data were acquired
with a mixing time of 150 ms. Data were processed using
standard apodizing functions prior to Fourier transformation.
2D 1H–13C HSQC NMR data were acquired, with 13C decou-
pling during the acquisition period, over an F2 frequency
width of 12 ppm into 2k complex data points. 16 to 32 tran-
sients were accumulated for each of 128 t1 increments over an
F1 frequency width of 180 ppm centered at 90 ppm. Phase-
sensitive data were acquired in a sensitivity-improved manner
using an echo-antiecho acquisition mode. 2D 1H–13C HMBC
NMR data were acquired over an F2 frequency width of 12
ppm into 2k complex data points. 64 to 96 transients were
accumulated for each of 128 t1 increments over an F1
frequency width of 200 ppm centered at 100 ppm. Phase-
sensitive data were acquired in a sensitivity-improved manner
using an echo-antiecho acquisition mode.This journal is © The Royal Society of Chemistry 2015Molecular dynamics
BBP starting structures were experimental X-ray structure or
their closest diastereoisomers built using Maestro (version 8.5).
The compounds 5, 8, 9, 14 and 18 were built with the peptide
building dictionary interface in Maestro. Parameters for
bridgehead lysine and glutamic acid were obtained from
natural amino acid building blocks based on transferability of
the AMBER force eld ﬀ99SB. The nal topologies, coordinates
and parameters for renement were then built using the Xleap
module from AMBER12 package. All minimization and MD
calculations were performed by the SANDER module of AMBER
12.0. There were two parts of MD simulations. The rst one was
a restraint MD simulated annealing (rMDSA) performed with
generalized-Born implicit solvent model (GB).42 A cutoﬀ of 8 A˚
was used for the non-bonded interactions. The simulation
started from a 500-step steepest descent energy minimization,
which followed by a period of 1 ns simulated annealing using
NOE distance restraints (Table S21†). The protocol involved: 5
ps of heating from 0 K to 600 K, 0.99 ns of slow cooling from 600
K to 100 K, and the last 10 ps of cooling to 0 K. The second MD
simulation was an oﬀ-restraint simulation starting with the
output structure of the rst rMDSA above as an input with
solvent corresponding to the NMR experiment: parameterized
DMSO43 for 1, 4, 10, 12, 13, and TIP3P44 water for all other BBPs.
The simulations used Langevin dynamics for temperature
regulation.45 Hydrogen bonds were constrained with the SHAKE
constraint algorithm,46 and the long-range electrostatic inter-
actions were handled by the particle-mesh Ewald (PME) proce-
dure.47 In addition, the non-bonded interactions used a cutoﬀ
of 8 A˚. In the second simulation, two stages of minimization
approaches were carried out. The rst stage involved only ions
and solvent molecular with 500 steps of steepest descent
minimization and 500 steps with conjugate gradient algorithm.
The second stage minimized the entire system with 2500 steps.
Next approach was 20 ps MD with weak restraints on the
peptide. During this approach, the system was heated from 0 K
to 300 K at constant volume. Finally, 1 ns MD on the entire
solute and solvent was performed using constant pressure
periodic boundary and 300 K constant temperature.Circular dichroism (CD)
Experiments were measured on a Jasco J-715 Spec-
tropolarimeter using Hellma Suprasil R 110-QS 0.1 cm cuvettes.
For each peptide, the measurements were performed in phos-
phate buﬀer (PB, pH ¼ 7.0, 10 mM), 25% 2,2,2-triuoroethanol
(TFE) in PB (pH ¼ 7.0, 10 mM), or in guanidinium chloride 6 M.
The concentration of the peptides was 0.25 mg mL1 and each
sample was measured via 3 accumulations. The scan rate was 10
nm min1, pitch 0.5 nm, response 16 s and bandwidth 1.0 nm.
The nitrogen ow was kept >5 L min1 throughout all
measurements. Before each measurement, the cuvettes were
washed successively with 1 M HCl, milli-Q H2O and PB. The
baseline was recorded under the same conditions and sub-
tracted automatically.Chem. Sci., 2015, 6, 5473–5490 | 5487
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View Article OnlineCapture compound mass spectrometry
Capture experiments were carried out in PCR strips according to
the general CCMS procedure.48 400 mg of HeLa cell lysate at 10
mg mL1 was pipetted for each set in triplicate. To the compe-
tition samples, 240 mM of BBP-competitor was added as a nal
concentration and incubated for 30 min at 4 C. Assay and
competition samples were then incubated with BBP-capture
compounds or BBP-scaﬀold controls at a nal concentration of
5 mM for 1 hour at 4 C on a rotating axis and irradiated for 10
min at 310 nm in a caproBox™ (caprotec bioanalytics GmbH) to
promote covalent cross-linking. Streptavidin-coated magnetic
beads (Invitrogen) were added to the samples and further
rotated for 1 hour at 4 C. The beads were collected using a
caproMag (caprotec bioanalytics GmbH) and washed 4 times
with washing buﬀer (caprotec bionanalytics GmbH) followed by
3 times washing with 80% acetonitrile and lastly resuspended
in MS-grade water. For tryptic digestion, the magnetic beads
were incubated with trypsin in 50 mM ammonium bicarbonate
for 16 hours at 37 C. The supernatant was recovered, evapo-
rated and stored at 20 C until mass spectrometry analysis.
Mass Spectrometry: Tryptic digests were analyzed by online
nanoow liquid chromatography tandem MS (LC-MSn) on an
UltiMate 3000 RSLCnano System (Dionex, part of Thermo
Fisher Scientic, Germany) coupled to a LTQ-Orbitrap Velos
instrument (Thermo Fisher Scientic, Germany) through a
Proxeon nanoelectrospray ion source (Proxeon, part of Thermo
Fisher Scientic, Germany). For chromatographic separation
samples were rst loaded on a reversed phase (RP) precolumn
(Acclaim PepMap100, 5 mm, 100 A˚, 100 mm i.d.  20 mm) and
separated on a RP analytical column (Acclaim PepMap RSLC
C18, 2 mm, 100 A˚, 75 mm i.d.  150 mm, Dionex, part of Thermo
Fisher Scientic, Germany) performing a 96 min gradient (5–45
% acetonitrile, 0.1% formic acid). MS detection was performed
in the data-dependent mode allowing to automatically switch
between Orbitrap-MS and LTQ-MS/MS acquisition in a top 20
conguration at 60 K resolution for a full scan with subsequent
collision induced dissociation (CID) fragmentation. Full scan
MS spectra (from m/z 300–2000) were acquired in the Orbitrap
analyzer aer accumulation to a target value of 1  106 in the
linear ion trap. The most intense ions (up to twenty, depending
on signal intensity) with charge state $2 were sequentially
isolated at a target value of 5000 and fragmented in the linear
ion trap using low energy CID with normalized collision energy
of 35%. Target ions already mass selected for CID were
dynamically excluded for the duration of 60 s. The minimal
signal required for MS2 was 1000 counts. An activation q of 0.25
and an activation time of 10 ms were applied for MS2 acquisi-
tions. All MS/MS data were analyzed using Andromeda imple-
mented in MaxQuant.33 Automated database searching against
the human UniProtKB/Swiss-Prot database was performed with
6 ppm precursor tolerance, 0.5 Da fragment ion tolerance, full
trypsin specicity allowing for up to 2 missed cleavages and
methionine oxidation as variable modication. The maximum
false discovery rates were set to 0.01 both on protein and
peptide level, the maximum PEP to 1, and 7 amino acids were
required as minimum peptide length. The label free5488 | Chem. Sci., 2015, 6, 5473–5490quantication option was selected with a maximal retention
time window of 2 min for the alignment between LC-MS/MS
runs.MicroScale thermophoresis
Human calmodulin (Enzo Life Sciences, Lausen, Switzerland)
was labeled using the RED-NHS Labeling kit (NanoTemper
Technologies). The labeling reaction was performed according
to the manufacturer's instructions in the supplied labeling
buﬀer applying a concentration of 20 mM protein (molar
dye : protein ratioz 2 : 1) at RT for 30 min. Unreacted dye was
removed with the supplied dye removal columns equilibrated
with MST buﬀer (50 mM TrisHCl pH 7.5, 150 mM NaCl, 10 mM
MgCl2). The label : protein ratio was determined using
photometry at 650 and 280 nm. Thereby, a ratio of 0.8 was
typically achieved. The labeled calmodulin was adjusted to 20
nM with MST buﬀer. 27c was dissolved in MST buﬀer and a
series of 16 1 : 1 dilutions was prepared in the identical buﬀer,
producing ligand concentrations ranging from 30.5 nM to 500
mM.
For thermophoresis, each ligand dilution was mixed with
one volume of labeled calmodulin, which leads to a nal
concentration of uorescently labeled calmodulin of 10 nM and
nal ligand concentrations ranging from 15.3 nM to 250 mM.
Aer 10 min incubation, followed by centrifugation at 10 000 
g for 10 min, approximately 4 mL of each solution was lled into
Monolith NT Standard Treated Capillaries (NanoTemper Tech-
nologies GmbH, Germany). Thermophoresis was measured
using a Monolith NT.115 instrument (NanoTemper Technolo-
gies GmbH) at an ambient temperature of 25 C with 5 s/30 s/5 s
laser oﬀ/on/oﬀ times, respectively. Instrument parameters were
adjusted with 15% LED power and 40% MST power. Data of
three independently pipetted measurements were analyzed
(NT.Analysis soware version 1.5.41, NanoTemper Technolo-
gies) using the signal from Thermophoresis + T-Jump. 28c was
used as negative control.Isothermal titration microcalorimetry
ITC experiments were performed using a MicroCal ITC200 from
GE Healthcare. 27c and 28c were dissolved in water to a
concentration of 0.7 and 0.6 mM, respectively. Calmodulin was
dissolved in water at 50 mM. Optionally CaCl2 (nal concentra-
tion 500 mM) or EDTA (nal concentration 1 mM) were added.
The peptide solution was injected into the calmodulin solution
(2.5 mL of peptide per injection at an interval of 180 s, a total of
15 injections into the cell volume of 200 mL, with stirring speed
of 800 rpm, at 25 C). The calmodulin solutions had a pH of 6.5
before and aer titration. The experimental data were tted to a
theoretical titration curve (“one set of sites” model) using so-
ware supplied by Microcal, with n (number of binding sites per
monomer), DH (binding enthalpy, kcal mol1) and Ka (associ-
ation constant, M1), as adjustable parameters. Thermody-
namic parameters were calculated from the Gibbs free energy
equation, DG ¼ DH  TDS ¼ RT ln Ka, where DG, DH, and DS
are the changes in free energy, enthalpy, and entropy ofThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinebinding, respectively. T is the absolute temperature, and R ¼
1.98 cal mol1 K1.
Serum stability assays
Human serum was diluted 1 : 4 in DMEM. Selected peptide was
diluted in TRIS buﬀer to a concentration of 400 mM. Aliquots of
peptide solution (50 mL) were added to aliquots of serum (50 mL)
in sterile Eppendorf tubes, to reach a peptide concentration of
200 mM during the assay. Samples were incubated at 37 celsius
degree under gentle stirring (350 rpm). Diﬀerent samples
(triplicate) were quenched at diﬀerent time points (0/1/3/6/24 h)
by precipitating serum proteins through the addition of
ZnSO4$7H2O (0.1 M, 100 mL) and cooling down in ice bath.
Protein precipitates were pelleted under centrifugation and the
supernatants were sampled and evaporated to dryness in a
centrifugal evaporator. Samples were resuspended in a H2O/
ACN (4 : 1) mixture and centrifuged again to remove residual
protein precipitate. Supernatants were then sampled and ana-
lysed by LC-MS. Experiment controls included a precipitation
control for each peptide, to test their resistance to the protein
precipitation conditions, and serum blanks, to check repro-
ducibility over diﬀerent serum batches. Two peaks originating
from DMEM, surviving the incubation in serum and the protein
precipitation conditions were used as internal standard.
PAMPA assays
The assays were performed according to the manufacturer's
protocol (Millipore, Billerica, MA, USA). Two (acceptor and
donor) multi-well plates were used. To the acceptor wells, 300
mL buﬀer (5% DMSO in PBS, pH 7.4) was added. Donor plate
consists of PVDF lter onto which 5 mL of lecithine in 5%
dodecane was applied as an articial membrane then imme-
diately 150 mL sample in buﬀer (0.2 mM) was added. Both plates
were incubated for 16 h at room temperature and the solution
from acceptor plate was analyzed by LCMS. Equilibrium solu-
tions are the mixture of volumes (i.e., 150 mL sample in buﬀer
and 300 mL buﬀer mixed manually) added to the donor and
acceptor wells. Later, these were analyzed by LCMS. Both
compounds and equilibrium solution in triplicates were
analyzed by LCMS. Carbamazepine is used as control and
analyzed parallel with compounds. Permeability of compounds
is calculated using the following formula. Calibration of Car-
bamazepine resulted in a linear curve and permeability value
showed a good correlation with theoretical permeability value
(Millipore) validating the assay. We did not observe any nor-
bornapeptide or N-methylated norbornapeptides transmission
into the acceptor plate.
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